Common approach to managing lower urinary tract symptoms and erectile dysfunction

Asian Journal of Andrology

Volumn 10, Issue 1, 2008, Pages 45-53

  Taylor, Jennifer M ^a   Desouza, Rowena ^a   Wang, Run ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; Medical therapy

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FINASTERIDE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAZOSIN; RHO KINASE; SILDENAFIL; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; UDENAFIL; VARDENAFIL; YOHIMBINE;

ADRENERGIC RECEPTOR BLOCKING; ASTHENIA; ATHEROSCLEROSIS; BLADDER EMPTYING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORPUS CAVERNOSUM; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EJACULATION DISORDER; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HOLMIUM LASER; HUMAN; LIBIDO; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; MINIMALLY INVASIVE SURGERY; MONOTHERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PREVALENCE; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URINE RETENTION; VASCULAR DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA; RHO-ASSOCIATED KINASES; TESTOSTERONE 5-ALPHA-REDUCTASE; UROLOGIC DISEASES;

EID: 37749045454     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00355.x     Document Type: Review

References (69)

1. Berry S, Coffey D, Walsh P, Ewing L. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
2. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997; 4: 40-6.
3. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the patho-physiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 2006; 38: 1-12.
4. NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. JAMA 1993; 270: 83-90.
5. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-8.
6. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
7. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: The UrEpik study. BJU Int 2003; 92: 719-25.
8. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical "Aging Male"symptoms?Results of the "Cologne Male Survey". Eur Urol 2003; 44: 588-94.
9. Rosen R, Altwein J, Boyle P, Kirby R, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49.
10. Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Sexual function. BJU Int 2005; 95 (Suppl 4): 12-8.
11. Miner M, Rosenberg M, Perelman M. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006; 28: 13-25.
12. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-51.
13. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B, and alpha1D-adrenoceptors in hyper-plastic and non-hyperplastic human prostate. J Urol 1999; 161: 635-40.
14. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, et al. Subtype specific regulation of human vascular alpha (1)-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 2336-43.
15. Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL, et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998; 160: 937-43.
16. Traish AM, Gupta S, Toselli P, de Tejada IS, Goldstein I, Moreland RB. Identification of alpha1-adrenergic receptor subtypes in human corpus cavernosum tissue and in cultured trabecular smooth muscle cells. Receptor 1995; 5: 145-57.
17. Traish AM, Moreland RB, Huang YH, Goldstein I. Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells. Recept Signal Transduct 1997; 7: 55-67.
18. Christ GH, Hodges S. Molecular mechanisms of detrusor and corporal myocyte contraction: Identifying targets for pharmacotherapy of bladder and erectile dysfunction. Br J Pharmacol 2006; 147 (Suppl 2): S41-55.
19. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: Mechanism for age-associated erectile dysfunction. FASEB J 2006; 20: 536-8.
20. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170: 2517-22.
21. Park K, Kim SW, Rhu KS, Paick JS. Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J Sex Med 2006; 3: 996-1003.
22. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997; 33: 1-8.
23. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97 (Suppl 2): 23-8.
24. Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: Association and management. Curr Urol Rep 2005; 6: 470-5.
25. AUA Guideline on the Management of Benign Prostatic Hyperplasia, Chapter 3. 2003.
26. Mottet N, Bressolle F, Delmas V, Robert M, Costa P. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003; 44: 101-5.
27. Noble AJ, Chess-Williams R, Couldwell C, Furakawa K, Uchyiuma T, Korstanje C, et al. The effects of tamsulosin, a high affinity antagonist at function alpha1A- and alpha1D-adrenoceptor subtypes. Br J Pharmacol 1997; 120: 231-8.
28. Pulito VL, Li X, Varga SS, Mulcahy LS, Clark KS, Halbert SA, et al. An investigation of the uroselective properties of four novel alpha (1a)-adrenergic receptor subtype-selective antagonists. J Pharm Exp Ther 2000; 294: 224-9.
29. Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003; 91: 873-7.
30. Nickel JC, Elhilali M, Emberton M, Vallancien G. The beneficial effects of alfuzosin 10 mg once daily in real-life practice on lower urinary tract symptoms, quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int 2006; 97: 1242-6.
31. Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res 2007; 19: 480-5.
32. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-61.
33. De Rose AF, Carmignani G, Corbu C, Giglio M, Traverso P, Naselli A, et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95-8.
34. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 2005; 95: 103-9.
35. Flomax (tamsulosin hydrochloride) Prescribing Information. Boehringer Ingelheim Pharmaceuticals and Astellas Pharma US, 2007.
36. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97 (Suppl 2): 34-8; discussion 44-5.
37. Barqawi AB, Myers JB, O'Donnell C, Crawford ED. The effect of alpha-blocker and 5 alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int 2007; 100: 853-7.
38. Kawabe K, Yoshida M, Homma Y. Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98: 1019-24.
39. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety plus Efficacy Canadian Two year Study. CMAJ 1996; 155: 1251-9.
40. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61: 579-84.
41. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007; 4: 1708-12.
42. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004; 6 (Suppl 9): S31-9.
43. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63.
44. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004; 171: 1194-8.
45. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related Surgery. Eur Urol 2004; 45: 620-7.
46. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater. J Urol 2006; 175: 217-20; discussion 220-1.
47. Kim CI, Chang HS, Kim BK, Park CH. Long-term results of medical treatment in benign prostatic hyperplasia. Urology 2006; 68: 1015-9.
48. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign pro-static hyperplasia. N Engl J Med 2003; 349: 2387-98.
49. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259-63.
50. Stief CG, Porst H, Evers T, Ulbrich E. Vardenafil in the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007; 177 (Suppl): 517.
51. Sairam K, Kulinskaya E, McNiholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-9.
52. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: Treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97 (Suppl 2): 39-43.
53. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind study. J Urol 2007; 177: 1071-7.
54. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7.
55. Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006; 7: 661-9.
56. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000; 12 (Suppl 1): S48-63.
57. Junemann KP, Alken P. Pharmacotherapy of erectile dysfunction: A review. Int J Impot Res 1989; 1: 71-93.
58. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52: 739-43.
59. Grimm RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8-14.
60. De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002; 14: 50-3.
61. Yassin A, Diede HE. Combination therapy: Alpha1-adrenoceptor blockade and tadalafil in BPH population. Int J Impot Res 2003; 15 (Suppl 6): 2-5.
62. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717-23.
63. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935-40.
64. Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67: 1199-204.
65. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: Focus on alpha-blocker interactions. Am J Cardiol 2005; 96: 42M-46M.
66. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332: 75-9.
67. Briganti A, Naspro R, Gallina A, Salonia A, Vavassori I, Hurle R, et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: Results of a prospective, 2-center, randomized trial. J Urol 2006; 175: 1817-21.
68. Kuntz RM, Ahyai S, Lehrick K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: A randomized prospective trial in 200 patients. J Urol 2004; 172: 1012-6.
69. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007; 29: 387-98.